Abstract
The renin-angiotensin-aldosterone system (RAAS) plays pivotal roles in the pathogenesis of progression of arterial hypertension, chronic kidney disease (CKD) and cardiovascular disease (CVD). Previous studies suggested that a direct renin inhibitor, aliskiren, may be effective for blood pressure lowering, renoprotection and cardiovascular protection. This review focuses on the effects of aliskiren for arterial hypertension, CKD and CVD.
Keywords: Aliskiren, angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, arterial hypertension, cardiovascular disease, chronic kidney disease, clinical trials, combination therapy, direct renin inhibitor, reni-angiotensinaldosterone system
34